Does anyone else think that there is something else at play here with the EMEA?
If Bronchiltol has no major safety issues and overall improves lung function by 8% why not approve it? The reason of variances between 6 year olds and adults seems rubbish. If everyone receives some benefit but in different percentages and you have no major safety risk what is the concern?
We have only 1 major approved product to compete with which earns over $400m revenue a year. A bit of a monopoly if ever there was one.
Does anyone else think that there is something else at play here...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $41.79M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 40000 | 4.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.6¢ | 234689 | 1 |
View Market Depth
| Last trade - 09.55am 12/07/2024 (20 minute delay) ? |
| SNT (ASX) Chart |
Day chart unavailable